OMIDRIA significantly improved postoperative day 1 visual acuity across a wide age range1
Of the 641 eyes of 389 patients who underwent cataract surgery, 260 eyes were administered phenylephrine 1.0%/ketorolac 0.3% and 381 eyes received epinephrine in the irrigation solution intraoperatively.1
Immediate improvement in postoperative visual acuity may be attributed to the anti-inflammatory properties of OMIDRIA.1
Single-center, retrospective case review (N=641)1
All patients received a topical NSAID regimen for 3 days before surgery and topical tropicamide 1.0%, cyclopentolate 1.0%, and phenylephrine 2.5% on the day of surgery.1
OMIDRIA reduces pain during and after surgery
The ketorolac component of intracameral OMIDRIA provides higher concentrations compared to topical drops2,3
Fewer drops are needed for cataract surgery, so there is a less demanding routine for you, your staff, and your patients2
OMIDRIA is easy to integrate into your surgical routine4
Prospective, single-masked, comparative study (N=60)5
All patients received preoperative topical lidocaine gel for anesthesia, administered 2-3 times 15 minutes before surgery.5 At the start of the surgery, all patients received 0.5 mL of intracameral preservative-free lidocaine 1%.5
Prospective, randomized, clinical trials (N=821)6
Preoperative treatments were standardized for all patients and included moxifloxacin 0.5% (Vigamox) treatment for at least 3 days before surgery, mydriatic treatment with topical phenylephrine HCl 2.5% plus tropicamide 1.0% three times in the 30 minutes before surgery, and lidocaine or tetracaine for local anesthesia on the day of surgery.6
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
You are leaving www.omidriahcp.com
Click below to Continue or Cancel to stay on this page.